Drugs / Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a

Follow last change Jul 2022 re-read 3 minutes ago

Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a

Developed for: sickle cell disease
Investigated by: Blood and Marrow Transplant Clinical Trials Network · California Institute for Regenerative Medicine (CIRM) · David Williams · Genetix Biotherapeutics Inc. · National Heart, Lung, and Blood Institute (NHLBI)

today NCT05353647 · Ph 2

20232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05353647	Jul 2022 → Oct 2027 expected	sickle cell disease	David Williams	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05353647 ↗
Modality	Cell therapy	“a single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a” NCT05353647 ↗
Route	Intravenous	“The transduced cells will be infused intravenously over 30-45 minutes” NCT05353647 ↗